Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of some unusual options trading on Thursday. Investors purchased 25,291 call options on the company. This represents an increase of 50% compared to the average volume of 16,872 call options.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.35 during midday trading on Thursday, reaching $3.54. The stock had a trading volume of 22,899,929 shares, compared to its average volume of 17,901,400. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $3.26 and its 200 day simple moving average is $3.32. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -3.40 and a beta of 1.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same quarter last year, the company earned ($0.41) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research report on Monday, August 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.06.

Insider Activity

In other news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. This represents a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,408 shares of company stock worth $434,976 in the last quarter. 6.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC acquired a new position in Recursion Pharmaceuticals in the second quarter valued at about $27,000. Integral Investment Advisors Inc. purchased a new position in Recursion Pharmaceuticals in the first quarter valued at $39,000. Sequoia Financial Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at $41,000. Finally, Fund Advisors of America Inc FL purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $45,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.